Initiation and regulation of complement during hemolytic transfusion reactions

Clinical and Developmental Immunology

Volumn 2012, Issue , 2012, Pages

  Stowell, Sean R ^a   Winkler, Anne M ^a   Maier, Cheryl L ^a   Arthur, C Maridith ^a   Smith, Nicole H ^a   Girard Pierce, Kathryn R ^a   Cummings, Richard D ^a   Zimring, James C ^b   Hendrickson, Jeanne E ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PUGET SOUND BLOOD CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIGEN; COMPLEMENT; INFUSION FLUID; LECTIN;

BLOOD TRANSFUSION REACTION; COMPLEMENT ACTIVATION; COMPLEMENT DEFICIENCY; ERYTHROCYTE TRANSFUSION; FATALITY; HEMOLYSIS; HUMAN; IMMUNITY; MICROORGANISM; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; BLOOD GROUP INCOMPATIBILITY; IMMUNOLOGY; METHODOLOGY;

ANIMALS; BLOOD GROUP INCOMPATIBILITY; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; ERYTHROCYTE TRANSFUSION; HEMOLYSIS; HUMANS;

EID: 84868681931     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2012/307093     Document Type: Review

References (152)

1. Litman G. W., Rast J. P., Fugmann S. D., The origins of vertebrate adaptive immunity. Nature Reviews Immunology 2010 10 8 543 553 2-s2.0-77954933984 10.1038/nri2807
2. Cannon J. P., Haire R. N., Rast J. P., Litman G. W., The phylogenetic origins of the antigen-binding receptors and somatic diversification mechanisms. Immunological Reviews 2004 200 12 22 2-s2.0-3242881303 10.1111/j.0105-2896. 2004.00166.x (Pubitemid 38998189)
3. Schwarz H. P., Dorner F., Karl Landsteiner and his his major contributions to haematology. British Journal of Haematology 2003 121 4 556 565 2-s2.0-0037716392 10.1046/j.1365-2141.2003.04295.x (Pubitemid 36645376)
4. Hajdu S. I., Blood transfusion from antiquity to the discovery of the Rh factor. Annals of Clinical and Laboratory Science 2003 33 4 471 473 2-s2.0-0142025356 (Pubitemid 37288660)
5. Landsteiner K., Zur Kenntnis der antifermativen, lytischen und agglutinierenden Wirkungendes Blutserums und der Lymphe. Zentralbl Bakteriol Parasitenkd 1900 27 357 363
6. Landsteiner K., Wiener A. S., Studies on an agglutinogen (Rh) in human blood reacting with anti-rhesus sera and with human isoantibodies. The Journal of Experimental Medicine 1941 74 309 320
7. Avery O. T., MacLeod C. M., McCarty M., Studies on the chemical nature of the substance inducing transformation of pneumococcal types. Induction of transformation by a desoxyribonucleic acid fraction isolated from Pneumococcus type III. Journal of Experimental Medicine 1944 79 137 158
8. Watson J. D., Crick F. H. C., Molecular structure of nucleic acids: a structure for deoxyribose nucleic acid. Nature 1953 171 4356 737 738 2-s2.0-0038497542 10.1038/171737a0
9. Sazama K., Transfusion errors: scope of the problem, consequences, and solutions. Current Hematology Reports 2003 2 518 521
10. Josephson C. D., Castillejo M. I., Grima K., Hillyer C. D., ABO-mismatched platelet transfusions: strategies to mitigate patient exposure to naturally occurring hemolytic antibodies. Transfusion and Apheresis Science 2010 42 1 83 88 2-s2.0-75949101859 10.1016/j.transci.2009.10.013
11. Salama A., Mueller-Eckhardt C., Delayed hemolytic transfusion reactions. Evidence for complement activation involving allogeneic and autologous red cells. Transfusion 1984 24 3 188 193 2-s2.0-0021183178 (Pubitemid 14107736)
12. Flickinger C., In search of red blood cells for alloimmunized patients with sickle cell disease. Immunohematology 2006 22 3 136 142 2-s2.0-33750451984 (Pubitemid 44655953)
13. Holers V. M., The spectrum of complement alternative pathway-mediated diseases. Immunological Reviews 2008 223 1 300 316 2-s2.0-47249120139 10.1111/j.1600-065X.2008.00641.x (Pubitemid 351986186)
14. Myhre B. A., The first recorded blood transfusions: 1656 to 1668. Transfusion 1990 30 4 358 362 2-s2.0-0025313868 (Pubitemid 20180831)
15. Galili U., Xenotransplantation and ABO incompatible transplantation: the similarities they share. Transfusion and Apheresis Science 2006 35 1 45 58 2-s2.0-33748467172 10.1016/j.transci.2006.05.007 (Pubitemid 44354321)
16. Sazama K., Reports of 355 transfusion-associated deaths: 1976 through 1985. Transfusion 1990 30 7 583 590 2-s2.0-0025158532 (Pubitemid 20317428)
17. Janatpour K. A., Kalmin N. D., Jensen H. M., Holland P. V., Clinical outcomes of ABO-incompatible RBC transfusions. American Journal of Clinical Pathology 2008 129 2 276 281 2-s2.0-40449118050 10.1309/VXY1ULAFUY6E6JT3 (Pubitemid 352029318)
18. Bacon J. M., Young I. F., ABO incompatible blood transfusion. Pathology 1989 21 3 181 184 2-s2.0-0024785574 (Pubitemid 20059774)
19. Hendriksen C. F., A short history of the use of animals in vaccine development and quality control. Developments in Biological Standardization 1996 86 3 10 2-s2.0-0029692291
20. Silverstein A. M., Bialasiewicz A. A., History of immunology. A history of theories of acquired immunity. Cellular Immunology 1980 51 1 151 167 2-s2.0-0018881316 (Pubitemid 10131461)
21. Enrlich P., Zur Theorie der Lysin Wirkung. Berliner Klinische Wochenschrift 1899 1 6 9
22. Walport M. J., Advances in immunology. Complement (second of two parts). The New England Journal of Medicine 2001 344 15 1140 1144 2-s2.0-0035849176 10.1056/NEJM200104123441506 (Pubitemid 32285236)
23. Walport M. J., Advances in immunology. Complement (first of two parts). The New England Journal of Medicine 2001 344 14 1058 1066 2-s2.0-0035810399 10.1056/NEJM200104053441406 (Pubitemid 32267977)
24. Pangburn M. K., Muller-Eberhard H. J., The alternative pathway of complement. Springer Seminars in Immunopathology 1984 7 2-3 163 192 2-s2.0-0021146002 (Pubitemid 14010635)
25. Fujita T., Evolution of the lectin complement pathway and its role in innate immunity. Nature Reviews Immunology 2002 2 5 346 353 2-s2.0-0036584407 (Pubitemid 37328757)
26. Engelfriet C. P., The immune destruction of red cells. Transfusion Medicine 1992 2 1 1 6 2-s2.0-0026836287
27. Lambris J. D., The multifunctional role of C3, the third component of complement. Immunology Today 1988 9 12 387 393 2-s2.0-0023796341
28. Gál P., Barna L., Kocsis A., Závodszky P., Serine proteases of the classical and lectin pathways: similarities and differences. Immunobiology 2007 212 4-5 267 277 2-s2.0-34249752746 10.1016/j.imbio.2006.11. 002 (Pubitemid 46825234)
29. Kang Y. S., Do Y., Lee H. K., Park S. H., Cheong C., Lynch R. M., Loeffler J. M., Steinman R. M., Park C. G., A Dominant Complement Fixation Pathway for Pneumococcal Polysaccharides Initiated by SIGN-R1 Interacting with C1q. Cell 2006 125 1 47 58 2-s2.0-33646005763 10.1016/j.cell.2006.01.046
30. Nordahl E. A., Rydengård V., Nyberg P., Nitsche D. P., Mörgelin M., Malmsten M., Björck L., Schmidtchen A., Activation of the complement system generates antibacterial peptides. Proceedings of the National Academy of Sciences of the United States of America 2004 101 48 16879 16884 2-s2.0-10044233893 10.1073/pnas.0406678101 (Pubitemid 39601332)
31. Ward P. A., Functions of C5a receptors. Journal of Molecular Medicine 2009 87 4 375 378 2-s2.0-64149093561 10.1007/s00109-009-0442-7
32. Müller-Eberhard H. J., The membrane attack complex of complement. Annual Review of Immunology 1986 4 503 528 2-s2.0-0022567063
33. Smith C. A., Pangburn M. K., Vogel C. W., Muller-Eberhard H. J., Molecular architecture of human properdin, a positive regulator of the alternative pathway of complement. Journal of Biological Chemistry 1984 259 7 4582 4588 2-s2.0-0021280352 (Pubitemid 14131365)
34. Fishelson Z., Pangburn M. K., Muller-Eberhard H. J., Characterization of the initial C3 convertase of the alternative pathway of human complement. Journal of Immunology 1984 132 3 1430 1434 2-s2.0-0021360385 (Pubitemid 14154572)
35. Seino J., Eveleigh P., Warnaar S., Van Haarlem L. J. M., Van Es L. A., Daha M. R., Activation of human complement by mouse and mouse/human chimeric monoclonal antibodies. Clinical and Experimental Immunology 1993 94 2 291 296 2-s2.0-0027484772 (Pubitemid 23337829)
36. Enriquez-Rincon F., Andrew E., Parkhouse R. M. E., Klaus G. G. B., Suppression of follicular trapping of antigen-antibody complexes in mice treated with anti-IgM or anti-IgD antibodies from birth. Immunology 1984 53 4 713 719 2-s2.0-0021682019 (Pubitemid 15209928)
37. Carroll M. C., The role of complement and complement receptors in induction and regulation of immunity. Annual Review of Immunology 1998 16 545 568 2-s2.0-0031921084 10.1146/annurev.immunol.16.1.545 (Pubitemid 28183376)
38. Yan J., Větvička V., Xia Y., Haniková M., Mayadas T. N., Ross G. D., Critical role of Kupffer cell CR3 (CD11b/CD18) in the clearance of IgM-opsonized erythrocytes or soluble β -glucan. Immunopharmacology 2000 46 1 39 54 2-s2.0-0342615080 10.1016/S0162-3109(99)00157-5 (Pubitemid 30026201)
39. Helmy K. Y., Katschke K. J. Jr., Gorgani N. N., Kljavin N. M., Elliott J. M., Diehl L., Scales S. J., Ghilardi N., Van Lookeren Campagne M., CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens. Cell 2006 124 5 915 927 2-s2.0-33644775720 10.1016/j.cell.2005.12.039 (Pubitemid 43344233)
40. Khera R., Das N., Complement Receptor 1: disease associations and therapeutic implications. Molecular Immunology 2009 46 5 761 772 2-s2.0-59249097049 10.1016/j.molimm.2008.09.026
41. Graham I. L., Anderson D. C., Holers V. M., Brown E. J., Complement receptor 3 (CR3, Mac-1, integrin α (M) β 2, CD11b/CD18) is required for tyrosine phosphorylation of paxillin in adherent and nonadherent neutrophils. Journal of Cell Biology 1994 127 4 1139 1147 2-s2.0-0028097582 10.1083/jcb.127.4.1139 (Pubitemid 24356000)
42. Taborda C. P., Casadevall A., CR3 (CD11b/CD18) and CR4 (CD11c/CD18) are involved in complement-independent antibody-mediated phagocytosis of Cryptococcus neoformans. Immunity 2002 16 6 791 802 2-s2.0-0036065586 10.1016/S1074-7613(02)00328-X (Pubitemid 34786478)
43. Brown E. J., Complement receptors and phagocytosis. Current Opinion in Immunology 1991 3 76 82
44. Prodeus A. P., Goerg S., Shen L. M., Pozdnyakova O. O., Chu L., Alicot E. M., Goodnow C. C., Carroll M. C., A critical role for complement in maintenance of self-tolerance. Immunity 1998 9 5 721 731 2-s2.0-0032211714 (Pubitemid 28557600)
45. Dempsey P. W., Allison M. E. D., Akkaraju S., Goodnow C. C., Fearon D. T., C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 1996 271 5247 348 350 2-s2.0-0030593030
46. Roozendaal R., Carroll M. C., Complement receptors CD21 and CD35 in humoral immunity. Immunological Reviews 2007 219 1 157 166 2-s2.0-34548599933 10.1111/j.1600-065X.2007.00556.x (Pubitemid 47390008)
47. Rittirsch D., Flierl M. A., Nadeau B. A., Day D. E., Huber-Lang M., Mackay C. R., Zetoune F. S., Gerard N. P., Cianflone K., Köhl J., Gerard C., Sarma J. V., Ward P. A., Functional roles for C5a receptors in sepsis. Nature Medicine 2008 14 5 551 557 2-s2.0-43249098418 10.1038/nm1753 (Pubitemid 351655216)
48. O'Neill G. J., Yang S. Y., Tegoli J., Chido and Rodgers blood groups are distinct antigenic components of human complement C4. Nature 1978 273 5664 668 670 2-s2.0-0018101172 (Pubitemid 8352554)
49. Lublin D. M., Kompelli S., Storry J. R., Reid M. E., Molecular basis of Cromer blood group antigens. Transfusion 2000 40 2 208 213 2-s2.0-0033976719 10.1046/j.1537-2995.2000.40020208.x (Pubitemid 30108992)
50. Botto M., Kirschfink M., Macor P., Pickering M. C., Würzner R., Tedesco F., Complement in human diseases: lessons from complement deficiencies. Molecular Immunology 2009 46 14 2774 2783 2-s2.0-68049123124 10.1016/j.molimm.2009.04.029
51. Seya T., Atkinson J. P., Functional properties of membrane cofactor protein of complement. Biochemical Journal 1989 264 2 581 588 2-s2.0-0024806255 (Pubitemid 20024531)
52. Nicholson-Weller A., Decay accelerating factor (CD55). Current Topics in Microbiology and Immunology 1992 178 7 30 2-s2.0-0026684224
53. Wilcox L. A., Ezzell J. L., Bernshaw N. J., Parker C. J., Molecular basis of the enhanced susceptibility of the erythrocytes of paroxysmal nocturnal hemoglobinuria to hemolysis in acidified serum. Blood 1991 78 3 820 829 2-s2.0-0025784367
54. Paccaud J. P., Carpentier J. L., Schifferli J. A., Direct evidence for the clustered nature of complement receptors type 1 on the erythrocyte membrane. Journal of Immunology 1988 141 11 3889 3894 2-s2.0-0023709391
55. Kim D. D., Song W. C., Membrane complement regulatory proteins. Clinical Immunology 2006 118 2-3 127 136 2-s2.0-32044432615 10.1016/j.clim.2005.10.014 (Pubitemid 43199649)
56. Huang Y., Fedarovich A., Tomlinson S., Davies C., Crystal structure of CD59: implications for molecular recognition of the complement proteins C8 and C9 in the membrane-attack complex. Acta Crystallographica D 2007 63 6 714 721 2-s2.0-34249054072 10.1107/S0907444907015557 (Pubitemid 46787696)
57. Farkas I., Baranyi L., Ishikawa Y., Okada N., Bohata C., Budai D., Fukuda A., Imai M., Okada H., CD59 blocks not only the insertion of C9 into MAC but inhibits ion channel formation by homologous C5b-8 as well as C5b-9. Journal of Physiology 2002 539 2 537 545 2-s2.0-0036521875 10.1113/jphysiol.2001.013381 (Pubitemid 35175407)
58. Rollins S. A., Sims P. J., The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. Journal of Immunology 1990 144 9 3478 3483 2-s2.0-0025233715 (Pubitemid 20146382)
59. Fujita T., Gigli I., Nussenzweig V., Human C4-binding protein. II. Role in proteolysis of C4b by C3b-inactivator. Journal of Experimental Medicine 1978 148 4 1044 1051 2-s2.0-0018073707 (Pubitemid 9034271)
60. Dodds A. W., Ren X. D., Willis A. C., Law S. K. A., The reaction mechanism of the internal thioester in the human complement component C4. Nature 1996 379 6561 177 179 2-s2.0-0030053692 10.1038/379177a0 (Pubitemid 26020202)
61. Gadjeva M., Dodds A. W., Taniguchi-Sidle A., Willis A. C., Isenman D. E., Law S. K. A., The covalent binding reaction of complement component C3. Journal of Immunology 1998 161 2 985 990 2-s2.0-0032528503 (Pubitemid 28323566)
62. Ferreira V. P., Pangburn M. K., Factor H-mediated cell surface protection from complement is critical for the survival of PNH erythrocytes. Blood 2007 110 6 2190 2192 2-s2.0-34548849449 10.1182/blood-2007-04-083170 (Pubitemid 47443939)
63. Davis A. E. III, Mejia P., Lu F., Biological activities of C1 inhibitor. Molecular Immunology 2008 45 16 4057 4063 2-s2.0-55949106824 10.1016/j.molimm.2008.06.028
64. Dempsey P. W., Fearon D. T., Complement: instructing the acquired immune system through the CD21/CD19 complex. Research in Immunology 1996 147 2 71 75 2-s2.0-0029980169 10.1016/0923-2494(96)87176-8 (Pubitemid 26180566)
65. Ollert M. W., David K., Bredehorst R., Vogel C. W., Classical complement pathway activation on nucleated cells: role of factor H in the control of deposited C3b. Journal of Immunology 1995 155 10 4955 4962 2-s2.0-0028884489
66. Heinen S., Hartmann A., Lauer N., Wiehl U., Dahse H. M., Schirmer S., Gropp K., Enghardt T., Wallich R., Hälbich S., Mihlan M., Schlötzer-Schrehardt U., Zipfel P. F., Skerka C., Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation. Blood 2009 114 12 2439 2447 2-s2.0-70349441306 10.1182/blood-2009-02- 205641
67. He J. Q., Wiesmann C., van Lookeren Campagne M., A role of macrophage complement receptor CRIg in immune clearance and inflammation. Molecular Immunology 2008 45 16 4041 4047 2-s2.0-55949119669 10.1016/j.molimm.2008.07.011
68. Duncan A. R., Winter G., The binding site for C1q on IgG. Nature 1988 332 6166 738 740 2-s2.0-0023897194
69. Weiner E. M., On the interaction of the first complement component C1 and its subunit C1q with solid-phase IgM immune complexes. Scandinavian Journal of Immunology 1988 28 4 425 430 2-s2.0-0024205544 (Pubitemid 19005302)
70. Swanson S. M., Dombrink-Kurtzman M. A., Voss E. W. Jr., C1q binding by a high affinity anti-fluorescein murine monoclonal IgM antibody and monomeric subunits. Molecular Immunology 1988 25 6 545 554 2-s2.0-0023890929 10.1016/0161-5890(88)90076-4
71. Schreiber A. D., Frank M. M., Role of antibody and complement in the immune clearance and destruction of erythrocytes. II. Molecular nature of IgG and IgM complement-fixing sites and effects of their interaction with serum. Journal of Clinical Investigation 1972 51 3 583 589 2-s2.0-0015310970
72. Jing Q. F., Mozdzanowska K., Gerhard W., Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype. Journal of Virology 2002 76 3 1369 1378 2-s2.0-0036145303 (Pubitemid 34066439)
73. Valim Y. M. L., Lachmann P. J., The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions. Clinical and Experimental Immunology 1991 84 1 1 8 2-s2.0-0025732287
74. Tao M. H., Canfield S. M., Morrison S. L., The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the C(H)2 domain. Journal of Experimental Medicine 1991 173 4 1025 1028 2-s2.0-0025759052
75. Roos A., Bouwman L. H., Van Gijlswijk-Janssen D. J., Faber-Krol M. C., Stahl G. L., Daha M. R., Human IgA activates the complement system via the Mannan-Binding lectin pathway. Journal of Immunology 2001 167 5 2861 2868 2-s2.0-0035451107 (Pubitemid 32768920)
76. Wright A., Morrison S. L., Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells. Journal of Immunology 1998 160 7 3393 3402 2-s2.0-0032055988 (Pubitemid 28164732)
77. Malhotra R., Wormald M. R., Rudd P. M., Fischer P. B., Dwek R. A., Sim R. B., Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nature Medicine 1995 1 3 237 243 2-s2.0-0028962403
78. Hennessey P. J., Black C. T., Andrassy R. J., Nonenzymatic glycosylation of immunoglobulin G impairs complement fixation. Journal of Parenteral and Enteral Nutrition 1991 15 1 60 64 2-s2.0-0025969283
79. Cutbush M., Mollison P. L., Relation between characteristics of blood-group antibodies in vitro and associated patterns of redcell destruction in vivo. British Journal of Haematology 1958 4 2 115 137 2-s2.0-0003116342
80. Howard J. E., Winn L. C., Gottlieb C. E., Clinical significance of the anti-complement component of antiglobulin antisera. Transfusion 1982 22 4 269 272 2-s2.0-0019945041 (Pubitemid 12038767)
81. Jones N. C., Mollison P. L., Veall N., Removal of incompatible red cells by the spleen. British Journal of Haematology 1957 3 2 125 133 2-s2.0-0000794395
82. Schirmer D. A., Song S. C., Baliff J. P., Harbers S. O., Clynes R. A., Krop-Watorek A., Halverson G. R., Czerwinski M., Spitalnik S. L., Mouse models of IgG- and IgM-mediated hemolysis. Blood 2007 109 7 3099 3107 2-s2.0-33947572932 10.1182/blood-2006-08-040139 (Pubitemid 46482113)
83. Liepkalns J. S., Hod E. A., Stowell S. R., Cadwell C. M., Spitalnik S. L., Zimring J. C., Biphasic clearance of incompatible red blood cells through a novel mechanism requiring neither complement nor Fcgamma receptors in a murine model. Transfusion. In press
84. Kumpel B. M., Monoclonal anti-D development programme. Transplant Immunology 2002 10 2-3 199 204 2-s2.0-0036342342 10.1016/S0966-3274(02)00066-7
85. Gorick B. D., Hughes-Jones N. C., Relative functional binding activity of IgG1 and IgG3 anti-D in IgG preparations. Vox Sanguinis 1991 61 4 251 254 2-s2.0-0025990069
86. Coopamah M. D., Freedman J., Semple J. W., Anti-D initially stimulates an Fc-dependent leukocyte oxidative burst and subsequently suppresses erythrophagocytosis via interleukin-1 receptor antagonist. Blood 2003 102 8 2862 2867 2-s2.0-0141889306 10.1182/blood-2003-04-1029 (Pubitemid 37248858)
87. Fudenberg H., Allen F. H., Transfusion reactions in the absence of demonstrable incompatibility. The New England Journal of Medicine 1957 256 25 1180 1184 2-s2.0-0011340523
88. Greenbury C. L., Moore D. H., Nunn L. A., The reaction with red cells of 7s rabbit antibody, its sub-units and their recombinants. Immunology 1965 8 420 431 2-s2.0-0000439629
89. Economidou J., Hughes-Jones N. C., Gardner B., Quantitative measurements concerning A and B antigen sites. Vox Sanguinis 1967 12 5 321 328 2-s2.0-0014085969
90. Rochna E., Hughes-Jones N. C., The use of purified 125-I-labelled anti-gamma globulin in the quantitative determination of D-antigen sites. Bibliotheca Haematologica 1965 23 490 491 2-s2.0-0013829149
91. Rochna E., Hughes-Jones N. C., The use of purified 125-I-labelled anti-gamma globulin in the determination of the number of D antigen sites on red cells of different phenotypes. Vox Sanguinis 1965 10 6 675 686 2-s2.0-0013812760
92. Hughes-Jones N. C., Gardner B., The Kell system studied with radioactively-labelled anti-K. Vox Sanguinis 1971 21 2 154 158 2-s2.0-0015100755
93. Nicolas V., Van Kim C. L., Gane P., Birkenmeier C., Cartron J. P., Colin Y., Mouro-Chanteloup I., Rh-RhAG/ankyrin-R, a new interaction site between the membrane bilayer and the red cell skeleton, is impaired by Rhnull-associated mutation. Journal of Biological Chemistry 2003 278 28 25526 25533 2-s2.0-0038491423 10.1074/jbc.M302816200 (Pubitemid 36835304)
94. Lee S., Russo D., Redman C., Functional and structural aspects of the Kell blood group system. Transfusion Medicine Reviews 2000 14 2 93 103 2-s2.0-0034031642 (Pubitemid 30196556)
95. Westhoff C. M., Reid M. E., Review: the Kell, Duffy, and Kidd blood group systems. Immunohematology 2004 20 1 37 49 2-s2.0-1442349704 (Pubitemid 38292746)
96. Westhoff C. M., The structure and function of the Rh antigen complex. Seminars in Hematology 2007 44 1 42 50 2-s2.0-33845725592 10.1053/j. seminhematol.2006.09.010 (Pubitemid 46013923)
97. Gardas A., Kościelak J., A, B and H blood group specificities in glycoprotein and glycolipid fractions of human erythrocyte membrane. Absence of blood group active glycoproteins in the membranes of non-secretors. Vox Sanguinis 1971 20 2 137 149 2-s2.0-0015016967
98. Springer G. F., Williamson P., Brandes W. C., Blood group activity of gram-negative bacteria. The Journal of Experimental Medicine 1961 113 1077 1093
99. Springer G. F., Horton R. E., Blood group isoantibody stimulation in man by feeding blood group-active bacteria. Journal of Clinical Investigation 1969 48 7 1280 1291 2-s2.0-0014541440
100. Storry J. R., Olsson M. L., The ABO blood group system revisited: a review and update. Immunohematology 2009 25 2 48 59 2-s2.0-70349578974
101. Woodrow J. C., Finn R., Krevans J. R., Rapid clearance of Rh positive blood during experimental Rh immunisation. Vox Sanguinis 1969 17 5 349 361 2-s2.0-0014597595
102. Samson D., Mollison P. L., Effect on primary Rh immunization of delayed administration of anti-Rh. Immunology 1975 28 2 349 357 2-s2.0-0016658034
103. Devey M. E., Voak D., A critical study of the IgG subclasses of Rh anti D antibodies formed in pregnancy and in immunized volunteers. Immunology 1974 27 6 1073 1079 2-s2.0-0016341201
104. Wagener F. A. D. T. G., Eggert A., Boerman O. C., Oyen W. J. G., Verhofstad A., Abraham N. G., Adema G., Van Kooyk Y., De Witte T., Figdor C. G., Heme is a potent inducer of inflammation in mice and is counteracted by heme oxygenase. Blood 2001 98 6 1802 1811 2-s2.0-0035885926 10.1182/blood.V98.6.1802
105. Simionatto C. S., Cabal R., Jones R. L., Galbraith R. A., Thrombophlebitis and disturbed hemostasis following administration of intravenous hematin in normal volunteers. American Journal of Medicine 1988 85 4 538 540 2-s2.0-0023755912
106. Rother R. P., Bell L., Hillmen P., Gladwin M. T., The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. Journal of the American Medical Association 2005 293 13 1653 1662 2-s2.0-15944398355 10.1001/jama.293.13.1653 (Pubitemid 40471796)
107. Baek J. H., D 'Agnillo F., Vallelian F., Pereira C. P., Williams M. C., Jia Y., Schaer D. J., Buehler P. W., Hemoglobin-driven pathophysiology is an in vivo consequence of the red blood cell storage lesion that can be attenuated in guinea pigs by haptoglobin therapy. The Journal of Clinical Investigation 2012 122 1444 1458
108. Krevans J. R., Jackson D. P., Conley C. L., Hartmann R. C., The nature of the hemorrhagic disorder accompanying hemolytic transfusion reactions in man. Blood 1957 12 9 834 843 2-s2.0-0001103845
109. Josephson C. D., Mullis N. C., Van Demark C., Hillyer C. D., Significant numbers of apheresis-derived group O platelet units have high-titer anti-A/A,B: implications for transfusion policy. Transfusion 2004 44 6 805 808 2-s2.0-2942587073 10.1111/j.1537-2995.2004.03290.x (Pubitemid 38738406)
110. Brown D. L., Lachmann P. J., Dacie J. V., The in vivo behaviour of complement-coated red cells: studies in C6-deficient, C3-depleted and normal rabbits. Clinical and Experimental Immunology 1970 7 3 401 421 2-s2.0-0014847966
111. Meryhew N. L., Runquist O. A., A kinetic analysis of immune-mediated clearance of erythrocytes. Journal of Immunology 1981 126 6 2443 2449 2-s2.0-0019494283 (Pubitemid 11072882)
112. Ruddy S., Austen K. F., C3b inactivator of man. II. Fragments produced by C3b inactivator cleavage of cell-bound or fluid phase C3b. Journal of Immunology 1971 107 3 742 750 2-s2.0-0015123385
113. Law S. K., Fearon D. T., Levine R. P., Action of the C3b-inactivator on cell-bound C3b. Journal of Immunology 1979 122 3 759 765 2-s2.0-0018404390 (Pubitemid 9145992)
114. Lachmann P. J., Pangburn M. K., Oldroyd R. G., Breakdown of C3 after complement activation. Identification of a new fragment, C3g, using monoclonal antibodies. Journal of Experimental Medicine 1982 156 1 205 216 2-s2.0-0019984714 (Pubitemid 12082499)
115. Engelfriet C. P., Von dem Borne A. E., Beckers D., Reynierse E., Van Loghem J. J., Autoimmune haemolytic anaemias. V. studies on the resistance against complement haemolysis of the red cells of patients with chronic cold agglutinin disease. Clinical and Experimental Immunology 1972 11 2 255 264 2-s2.0-0015353108
116. Jaffe C. J., Atkinson J. P., Frank M. M., The role of complement in the clearance of cold agglutinin sensitized erythrocytes in man. Journal of Clinical Investigation 1976 58 4 942 949 2-s2.0-0017099401
117. Akeroyd J. H., O'Brien W. A., Survival of group AB red cells in a group A recipient. Vox Sanguinis 1958 3 5 330 335 2-s2.0-51749114288
118. Jandl J. H., Simmons R. L., The agglutination and sensitization of red cells by metallic cations: interactions between multivalent metals and the red-cell membrane. British Journal of Haematology 1957 3 19 38
119. Qin X., Goldfine A., Krumrei N., Grubissich L., Acosta J., Chorev M., Hays A. P., Halperin J. A., Glycation inactivation of the complement regulatory protein CD59: a possible role in the pathogenesis of the vascular complications of human diabetes. Diabetes 2004 53 10 2653 2661 2-s2.0-4644304889 10.2337/diabetes.53.10.2653 (Pubitemid 39299275)
120. Waitumbi J. M., Donvito B., Kisserli A., Cohen J. H. M., Stoute J. A., Age-related changes in red blood cell complement regulatory proteins and susceptibility to severe malaria. Journal of Infectious Diseases 2004 190 6 1183 1191 2-s2.0-4444340345 10.1086/423140 (Pubitemid 39186807)
121. Win N., Doughty H., Telfer P., Wild B. J., Pearson T. C., Hyperhemolytic transfusion reaction in sickle cell disease. Transfusion 2001 41 3 323 328 2-s2.0-0035084531 10.1046/j.1537-2995.2001.41030323.x (Pubitemid 32238528)
122. Salama A., Mueller-Eckhardt C., Binding of fluid phase C3b to nonsensitized bystander human red cells. A model for in vivo effects of complement activation on blood cells. Transfusion 1985 25 6 528 534 2-s2.0-0022346822 (Pubitemid 16174461)
123. Wang R. H., Phillips G. Jr., Medof M. E., Mold C., Activation of the alternative complement pathway by exposure of phosphatidylethanolamine and phosphatidylserine on erythrocytes from sickle cell disease patients. Journal of Clinical Investigation 1993 92 3 1326 1335 2-s2.0-0027181206 (Pubitemid 23273908)
124. Test S. T., Woolworth V. S., Defective regulation of complement by the sickle erythrocyte: evidence for a defect in control of membrane attack complex formation. Blood 1994 83 3 842 852 2-s2.0-0028040030 (Pubitemid 24043748)
125. Reyes M. A., Illoh O. C., Hyperhemolytic transfusion reaction attributable to anti-Fy3 in a patient with sickle cell disease. Immunohematology 2008 24 2 45 51 2-s2.0-48849107835
126. Strait R. T., Hicks W., Barasa N., Mahler A., Khodoun M., Kohl J., Stringer K., Witte D., Van Rooijen N., Susskind B. M., MHC class I-specific antibody binding to nonhematopoietic cells drives complement activation to induce transfusion-related acute lung injury in mice. The Journal of Experimental Medicine 2011 208 2525 2544
127. Shaz B. H., Stowell S. R., Hillyer C. D., Transfusion-related acute lung injury: from bedside to bench and back. Blood 2011 117 5 1463 1471 2-s2.0-79551639702 10.1182/blood-2010-04-278135
128. Silliman C. C., Dzieciatkowska M., Moore E. E., Kelher M. R., Banerjee A., Liang X., Land K. J., Hansen K. C., Proteomic analyses of human plasma: Venus versus Mars. Transfusion 2012 52 417 424
129. Sahu A., Kay B. K., Lambris J. D., Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. Journal of Immunology 1996 157 2 884 891 2-s2.0-0030013492 (Pubitemid 26231396)
130. Inagi R., Miyata T., Hong K., Pramoonjago P., Maeda K., Inoue K., Decreased activity of complement-mediated immune complex clearance in hemodialysis patients. Clinical Immunology and Immunopathology 1993 68 3 333 339 2-s2.0-0027365485 10.1006/clin.1993.1135 (Pubitemid 23284093)
131. Miyata T., Fujita Y., Inagi R., Inoue I., Sugiyama S., Maeda K., Effectiveness of nafamostat mesilate on glomerulonephritis in immune-complex diseases. The Lancet 1993 341 8856 1353 2-s2.0-0027175686 (Pubitemid 23148137)
132. Weisman H. F., Bartow T., Leppo M. K., Marsh H. C., Carson G. R., Concino M. F., Boyle M. P., Roux K. H., Weisfeldt M. L., Fearon D. T., Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990 249 4965 146 151 2-s2.0-0025354456
133. Piddlesden S. J., Jiang S., Levin J. L., Vincent A., Morgan B. P., Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis. Journal of Neuroimmunology 1996 71 1-2 173 177 2-s2.0-0030560757 10.1016/S0165-5728(96)00144-0 (Pubitemid 26413270)
134. Pruitt S. K., Baldwin W. M. III, Marsh H. C. Jr., Lin S. S., Yeh C. G., Bollinger R. R., The effect of soluble complement receptor type 1 on hyperacute xenograft rejection. Transplantation 1991 52 5 868 873 2-s2.0-0025750106
135. Roos A., Nauta A. J., Broers D., Faber-Krol M. C., Trouw L. A., Drijfhout J. W., Daha M. R., Specific inhibition of the classical complement pathway by C1q-binding peptides. Journal of Immunology 2001 167 12 7052 7059 2-s2.0-0035892756 (Pubitemid 33144201)
136. Mqadmi A., Zheng X., Song J., Abramowitz S., Giclas P., Yazdanbakhsh K., Prevention of complement-mediated immune hemolysis by a small molecule compound. Biochemical and Biophysical Research Communications 2004 325 4 1465 1471 2-s2.0-8844229050 10.1016/j.bbrc.2004.11.002 (Pubitemid 39535927)
137. Mqadmi A., Abdullah Y., Yazdanbakhsh K., Characterization of complement receptor 1 domains for prevention of complement-mediated red cell destruction. Transfusion 2005 45 2 234 244 2-s2.0-13144303521 10.1111/j.1537-2995.2004.04163. x (Pubitemid 40180141)
138. Spitzer D., Unsinger J., Bessler M., Atkinson J. P., ScFv-mediated in vivo targeting of DAF to erythrocytes inhibits lysis by complement. Molecular Immunology 2004 40 13 911 919 2-s2.0-0346023953 10.1016/j.molimm.2003.10.017 (Pubitemid 38077035)
139. Basta M., Langlois P. F., Marques M., Frank M. M., Fries L. F., High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance. Blood 1989 74 1 326 333 2-s2.0-0024409922 (Pubitemid 19187448)
140. Basta M., Fries L. F., Frank M. M., High doses of intravenous Ig inhibit in vitro uptake of C4 fragments onto sensitized erythrocytes. Blood 1991 77 2 376 380 2-s2.0-0026022353
141. Hillmen P., Hall C., Marsh J. C. W., Elebute M., Bombara M. P., Petro B. E., Cullen M. J., Richards S. J., Rollins S. A., Mojcik C. F., Rother R. P., Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. The New England Journal of Medicine 2004 350 6 552 559 2-s2.0-10744228553 10.1056/NEJMoa031688 (Pubitemid 38160785)
142. Moller G., Survival of H-2 incompatible mouse erythrocytes in untreated and isoimmune recipients. Immunology 1965 8 360 374 2-s2.0-78651172638
143. Evans R. S., Turner E., Bingham M., Chronic hemolytic anemia due to cold agglutinins: the mechanism of resistance of red cells to C' hemolysis by cold agglutinins. Journal of Clinical Investigation 1967 46 9 1461 1474 2-s2.0-0014127467
144. Evans R. S., Turner E., Bingham M., Woods R., Chronic hemolytic anemia due to cold agglutinins. II. The role of C' in red cell destruction. Journal of Clinical Investigation 1968 47 4 691 701 2-s2.0-0014278350
145. Mollison P. L., Cutbush M., Use of isotope-labelled red cells to demonstrate incompatibility in vivo. The Lancet 1955 265 6878 1290 1295 2-s2.0-50449144871
146. Thomas K. R., Capecchi M. R., Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell 1987 51 3 503 512 2-s2.0-0023646810
147. Mak T. W., Penninger J. M., Ohashi P. S., Knockout mice: a paradigm shift in modern immunology. Nature Reviews Immunology 2001 1 1 11 19 2-s2.0-0035495829 (Pubitemid 33741971)
148. Campbell-Lee S. A., Liu J., Velliquette R. W., Halverson G. R., Shirey R. S., Chaudhuri A., Reid M. E., Ness P. M., Baldwin W. M., The production of red blood cell alloantibodies in mice transfused with blood from transgenic Fyb-expressing mice. Transfusion 2006 46 10 1682 1688 2-s2.0-33748935784 10.1111/j.1537-2995.2006.00966.x (Pubitemid 44435719)
149. Desmarets M., Cadwell C. M., Peterson K. R., Neades R., Zimring J. C., Minor histocompatibility antigens on transfused leukoreduced units of red blood cells induce bone marrow transplant rejection in a mouse model. Blood 2009 114 11 2315 2322 2-s2.0-70349563774 10.1182/blood-2009-04-214387
150. Smith N. H., Henry K. L., Cadwell C. M., Bennett A., Hendrickson J. E., Frame T., Zimring J. C., Generation of transgenic mice with antithetical KEL1 and KEL2 human blood group antigens on red blood cells. Transfusion. In press 10.1111/j.1537-2995.2012.03641.x
151. Smith N. H., Hod E. A., Spitalnik S. L., Zimring J. C., Hendrickson J. E., Transfusion in the absence of inflammation induces antigen-specific tolerance to murine RBCs. Blood 2012 119 1566 1569
152. US Dept of Health and Human Services, Fatalities Reported to the FDA Following Blood Collection, 2011